
To perform a post hoc analysis of the FIGHT trial, evaluating the effect of liraglutide on the totality of events in patients with heart failure with reduced ejection fraction (HFrEF). Compared to placebo, there was a trend towards increased risk with liraglutide of total HF hospitalizations or all‐cause deaths and arrhythmias. In patients with HFrEF, liraglutide might increase the risk of cardiovascular adverse effects, possibly driven by the excess risk of arrhythmias and worsening HF events. As this was a post hoc analysis, these results should be interpreted as exploratory and hypothesis‐generating.
Like
Save
Share